SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22: 1–12.
  • 2
    Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63: 395401.
  • 3
    Jantti J, Aho K, Kaarela K, Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20-year study. Rheumatology (Oxford) 1999; 38: 113841.
  • 4
    Coyte P, Asche C, Croxford R, Chan B. The economic cost of arthritis and rheumatism in Canada. Toronto: Institute for Clinical Evaluative Sciences; 1998.
  • 5
    Backman CL. Employment and work disability in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 14852.
  • 6
    Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 16815.
  • 7
    Allaire S, Wolfe F, Niu J, LaValley M, Michaud K. Work disability and its economic effect on 55–64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005; 53: 6038.
  • 8
    Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007; 56: 1397407.
  • 9
    Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 120918.
  • 10
    Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000; 39: 2833.
  • 11
    Pucino F Jr, Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: where are we going? Am J Health Syst Pharm 2006; 63: S1941.
  • 12
    Kasmann NM, Power JD, Mamdani MM, Badley EM. Use of medication. In: Badley EM, Glazier RH, editors. Arthritis and related conditions in Ontario: ICES research atlas. 2nd ed. Toronto: Institute for Clinical Evaluative Sciences; 2004. p. 87104.
  • 13
    Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NY Hosp Jt Dis 2008; 66: 7785.
  • 14
    Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis 2010; 69: 86871.
  • 15
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 96475.
  • 16
    Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2011; 63: 6578.
  • 17
    Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewe R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 9951003.
  • 18
    Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 156370.
  • 19
    Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010; 12: R35.
  • 20
    Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making 2007; 27: 13850.
  • 21
    Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol 2007; 36: 17983.
  • 22
    Scott DL, Kingsley G. Clinical effectiveness of biologics in clinical practice. Arthritis Res Ther 2010; 12: 115.
  • 23
    Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24: 71925.
  • 24
    Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24: 438.
  • 25
    Agency for Healthcare and Research Quality. MEPS HC-121: 2008 full year consolidated data file. 2010. URL: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h121/ h121doc.pdf.
  • 26
    Ezzati-Rice TM, Rohde F, Greenblatt J. Sample design of the medical expenditure panel survey household component, 1998–2007. Methodology Report No. 22. 2008. URL: http://www.meps.ahrq.gov/mepsweb/data_files/publications/mr22/mr22.pdf.
  • 27
    Stata statistical software: release 11. College Station (TX): Stata Corporation; 2009.
  • 28
    Agency for Healthcare and Research Quality. Healthcare cost and utilization project (HCUP). 2011. URL: http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
  • 29
    Agency for Healthcare and Research Quality. MEPS HC-120: 2008 medical conditions. 2010. URL: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h120/h120doc.pdf.
  • 30
    Li B, Evans D, Faris P, Dean S, Quan H. Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases. BMC Health Serv Res 2008; 8: 12.
  • 31
    Manning W. Dealing with skewed data on costs and expenditures. Cheltenham (UK): Edward Elgar Publishing; 2006.
  • 32
    Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17: 28395.
  • 33
    Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005; 24: 46588.
  • 34
    Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 46194.
  • 35
    Partha D, Manning WG, Norton E. Modeling health care costs and counts. ASHE. 2010. Cornell University.
  • 36
    Greene W. Econometric analysis. 5th ed. Upper Saddle River (NJ): Prentice Hall; 2002.
  • 37
    Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29: 30520.
  • 38
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 76284.
  • 39
    Sullivan PW, Ghushchyan V, Huang XY, Globe DR. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010; 37: 5449.
  • 40
    Stagnitti M. Trends in health care expenditures by body mass index (BMI) category for adults in the US civilian noninstitutionalized population, 2001 and 2006. Rockville (MD): Agency for Healthcare Research and Quality; 2009.
  • 41
    Stanton M. The high concentration of US health care expenditures. Rockville (MD): Agency for Healthcare Research and Quality; 2006.
  • 42
    Cisternas MG, Murphy LB, Yelin EH, Foreman AJ, Pasta DJ, Helmick CG. Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005. J Rheumatol 2009; 36: 25318.
  • 43
    Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 2003; 289: 322930.
  • 44
    Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 70412.
  • 45
    Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008; 66: 7785.
  • 46
    Yelin E, Cisternas MG, Pasta DJ, Trupin L, Murphy L, Helmick CG. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum 2004; 50: 231726.
  • 47
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007; 23: 174959.